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Abstract
Background: Glucose tolerance testing is a tool used to estimate glucose
effectiveness and insulin sensitivity in diabetic patients. The importance of such
tests has prompted the development and utilisation of mathematical models that
describe glucose kinetics as a function of insulin activity. The hormone glucagon,
also plays a fundamental role in systemic plasma glucose regulation and is
secreted reciprocally to insulin, stimulating catabolic glucose utilisation. However,
regulation of glucagon secretion by α-cells is impaired in type-1 and type-2
diabetes through pancreatic islet dysfunction. Despite this, inclusion of glucagon
activity when modelling the glucose kinetics during glucose tolerance testing is
often overlooked. This study presents two mathematical models of a glucose
tolerance test that incorporate glucose-insulin-glucagon dynamics. The first
model describes a non-linear relationship between glucagon and glucose, whereas
the second model assumes a linear relationship.
Results: Both models are validated against insulin-modified and glucose infusion
intravenous glucose tolerance test (IVGTT) data, as well as insulin infusion data,
and are capable of estimating patient glucose effectiveness (sG) and insulin
sensitivity (sI). Inclusion of glucagon dynamics proves to provide a more detailed
representation of the metabolic portrait, enabling estimation of two new
diagnostic parameters: glucagon effectiveness (sE) and glucagon sensitivity (δ).
Conclusions: The models are used to investigate how different degrees of patient
glucagon sensitivity and effectiveness affect the concentration of blood glucose
and plasma glucagon during IVGTT and insulin infusion tests, providing a
platform from which the role of glucagon dynamics during a glucose tolerance
test may be investigated and predicted.
Keywords: Glucagon Sensitivity; Glucagon Effectiveness; Intravenous Glucose
Tolerance Test; Non-Linear Glucagon Minimal Model; Linear Glucagon Minimal
Model; Glucose-Insulin-Glucagon Dynamics; Minimal Model1
2
Background3
Glucose is the fundamental source of cellular energy, maintained in a precise range4
in the blood (70 - 110 mg/dl, 4-7 mM) to facilitate general body function [1, 2].5
Systemic glucose concentration is tightly regulated by the pancreatic islets, which6
secrete several hormones that directly influence the metabolic pathways respon-7
sible for its utilisation and production [3]. Insulin and glucagon are the two most8
prominent hormones responsible for normoglycaemia, secreted by β-cells and α-cells9
respectively, in response to deviations in plasma glucose levels [4]. Insufficient secre-10
tion or hypoactivity of insulin can lead to diabetes mellitus; a metabolic disorder11
characterised by persistent hyperglycaemia. While diabetes has long been linked12
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to impaired insulin secretion, recently, glucagon has received much attention with13
respect to its role in diabetes. Evidence suggests that hypersecretion of glucagon14
can dysregulate glucose homeostasis by initiating and maintaining hyperglycaemic15
conditions [5]. Unger and Cherrington have subsequently suggested that “glucagon16
excess rather than insulin deficiency, is the sine qua non of diabetes” [6]. While the17
mechanisms of glucagon regulation by glucose are still debated [7], pharmacological18
manipulation of glucagon release could potentially improve diabetic glucose regula-19
tion [3]. According to the world health organisation (WHO), high blood glucose will20
contribute to almost half of all deaths before the age of 70, with diabetes projected21
to be the seventh leading cause of death by 2030 [8]. Such trends undoubtedly imply22
an increase in strain on health services to meet patient demands [9] and as such, any23
methods that facilitate mechanistic understanding or aid earlier detection of peo-24
ple at risk of diabetes will significantly decrease the financial and healthcare burden.25
26
The glucose tolerance test (GTT) is a common diagnostic tool used to assess pre-27
diabetic and diabetic conditions, by measuring changes in blood glucose and insulin28
after exposure to a large bolus of glucose. Such tests are available in different forms,29
for example, the intravenous glucose tolerance test (IVGTT) is used to estimate30
insulin sensitivity (sI), glucose effectiveness (sG), insulin secretion and beta cell31
function in diabetic patients [10]. Mathematical IVGTT models widely accompany32
the analysis of IVGTT results and are used to improve the understanding of blood33
glucose regulation, offering insights into the relationships between key components34
and to speculate the effects of population considerations [11].35
Bolie et al (1961) was the first to develop a mathematical model of the IVGTT,36
proposing a coupled system of two linear, ordinary differential equations (ODEs)37
that describe the behaviour of glucose and insulin in response to administered glu-38
cose [12]. This model is simple and may be solved analytically, but assumes glucose39
disappearance is a linear function of plasma insulin concentration and that both40
secretion and disappearance rates are proportional to blood glucose and insulin lev-41
els. These assumptions are highly idealised and are not sufficient to fully describe42
the complicated relationship that exists in glucose-insulin dynamics. Ackerman et43
al (1965) also made an impact on early studies of glucose modelling by proposing44
a simple linear model to describe the interaction between insulin and glucose [13].45
More sophisticated models were introduced in later studies, including the well-46
known Minimal Model, which was derived to analyse the behaviour of blood glucose47
during an IVGTT [14]. This model concentrates solely on glucose-insulin dynamics48
but considers separately the concentration of insulin in plasma and the amount of49
insulin dependent glucose uptake in tissue (termed interstitial). While this model is50
simple and cannot be solved analytically, its ability to return estimates for glucose51
effectiveness and insulin sensitivity, which are key parameters for diabetes diagno-52
sis, is advantageous. Indeed, this model has been praised for its contribution to53
diabetology [15] and has been widely used since its inception [16].54
Modern iterations of the minimal model have been adapted to better represent free55
fatty acid kinetics, as well as glucose dynamics, during insulin-modified intravenous56
glucose tolerance testing (IMIVGTT) [17]. Indeed, Thomaseth et al evaluate how57
well mathematical models of glucose and free fatty acid kinetics perform in the pres-58
ence of a counterregulatory response (CRR). Such a response is triggered during an59
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IMIVGTT as a result of administration of insulin, which can induce hypoglycaemia60
in healthy insulin-sensitive patients. This results in the accuracy of such mathemat-61
ical models that do not account for a CRR to be undermined [17]. Thomaseth et al62
modified the minimal model to improve its predictions for both glucose dynamics63
and free fatty acid kinetics, by introducing a glucose concentration threshold as a64
signal for a CRR. Indeed, their results suggest that glucagon fits well as a CRR65
hormone within their modelling framework, while also reporting that inclusion of66
other CRR hormones (epinephrine, norepinephrine, growth hormone and cortisol)67
did not improve model predictions.68
Despite the simplicity and widespread use of the Minimal Model, it does have69
some significant limitations. A major criticism of the model is that it delivers70
mathematically unrealistic results [18], predicting that interstitial insulin activity71
becomes infinite over long time-periods [19]. These authors subsequently developed72
a non-linear model of the IVGTT which again, considers glucose-insulin dynam-73
ics only, but possesses a steady state solution that all model solutions converge.74
Another drawback of the Minimal Model is that it does not consider the effects75
of glucagon, preventing it from completely representing the full metabolic portrait76
of an individual. However, this is understandable as the role of glucagon with re-77
spect to diabetes became prevalent long after the inception of the minimal model.78
Comprehensive models of glucose metabolism that include regulation via insulin,79
glucagon and epinephrine do exist [20, 21], however, such models are considerably80
more complex and are often deployed to probe bioenergetic mechanisms, rather than81
glucose dynamics during glucose tolerance testing. The role of glucagon becomes82
crucial when blood glucose levels are low as it ensures that a sufficient amount of83
glucose is produced in order to avoid unconsciousness, brain damage and the other84
risks posed by hypoglycaemia. The risk of hypoglycaemia is increased for diabetics,85
due to either an impaired response of the alpha cells in the pancreas [22], or as a86
side effect of insulin therapy [23] and can require an additional supply of exogenous87
glucagon to be administered.88
89
This study aims to investigate the interaction between glucose, insulin and90
glucagon during a clinical test by developing two new mathematical models that91
focus exclusively on glucose-insulin-glucagon dynamics. Both models are designed92
to simulate the perturbations in the blood-glucose regulatory system, caused by a93
rapid infusion / injection of either glucose, insulin or glucagon. As a result, both94
models are able to accurately represent behaviour during an IVGTT and during95
tests that involve the intravenous infusion of insulin. Consequently, IVGTT and96
insulin-infusion data is used to validate the accuracy of both models.97
Two new parameters, termed glucagon effectiveness and glucagon sensitivity, are98
defined in this paper and both quantities help to determine a patient’s respon-99
siveness to glucagon. This work investigates the response of normal and diabetic100
patients to exogenous infusions of insulin, to determine how inter-individual varia-101
tion in glucagon sensitivity / effectiveness potentially affects a patient’s ability to102
re-stabilise their blood glucose concentration to a safe level.103
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Methods104
The models presented in this work describe the interactions between glucose and105
insulin in the same way as the Minimal Model [16], but incorporate additional106
equations to describe glucose-insulin-glucagon dynamics (Figure 1). The two mod-107
els, however, treat the interactions between glucagon and glucose very differently.108
Figure 1: Model schematics Model schematics for the linear glucagon minimal
model (LGMM) and non-linear minimal model (NLGMM). Model variables are
described as: G, glucose; I, plasma insulin; X, active insulin; E, plasma glucagon
and Y, active glucagon. Solid lines depict processes whereas dashed lines depict
regulatory-dependent events. Parameter values are described in Table 1. Both
models describe the hormonal regulation of plasma glucose concentration during
hyperglycaemia ([G] > 120 mg/dl) and hypoglycaemia ([G] < 70 mg/dl), with the
NLGMM additionally considering interstitial glucagon dynamics, [E], [Y], whereas
the LGMM assumes a linear relationship whereby plasma glucose will increase in
proportion to the concentration of glucagon, [E], in the plasma above the basal
level.
Symbol Description Unit
G(t) Plasma Glucose concentration at time t mg/dl
I(t) Plasma Insulin concentration at time t µU/ml
X(t) Interstitial Insulin activity at time t min−1
Y (t) Interstitial Glucagon activity at time t min−1
E(t) Plasma Glucagon concentration at time t pg/ml
Gb Baseline plasma glucose concentration mg/dl
Ib Baseline plasma insulin concentration µU/ml
Eb Baseline plasma glucagon concentration ng/l
G0 Theoretical value of plasma glucose concentration at time t = 0 mg/dl
I0 Theoretical value of plasma insulin concentration at time t = 0 µU/ml
p1 Glucose Effectiveness min−1
p2 Rate of clearance of interstitial insulin min−1
p3 Rate of excess plasma insulin stimulated glucose activity min−2(µU/ml)−1
p4 Rate of insulin disappearance from plasma min−1
p5 Rate of second phase insulin secretion (glucose dependent) µU/ml min−2(mg/dl)−1
p6 Rate of glucagon disappearance from plasma min−1
p7 Rate of excess plasma glucagon stimulated glucagon activity ng/l min−2(mg/dl)−1
p8 Rate of clearance of interstitial glucagon min−1
p9 Rate of excess plasma glucagon stimulated glucose activity min−1(ng/l)−1
p11 Maximum rate at which insulin suppresses glucagon secretion ng/l min−1
δ Glucagon effectiveness mg/dl min−1 (ng/l)−1
Table 1: A description of the different variables and parameters that appear within
both the LGMM and NLGMM.
Non-Linear Glucagon Minimal Model Formulation (NLGMM)109
The first system extends the Minimal Model and assumes a complex, non-linear110
relationship between glucose and glucagon, and glucagon and insulin. This model111
is therefore denoted as the Non-Linear Glucagon Minimal Model (NLGMM).112
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The NLGMM consists of the following equations:
dG
dt
= −p1(G−Gb) + (Y −X)G+Ginf(t), (1)
dX
dt
= −p2X + p3(I − Ib), (2)
dI
dt
= −p4(I − Ib) + p5(G−Gb)+t+ Iinf(t), (3)
dE
dt







= −p8Y + p9(E − Eb)+. (5)
When modelling an IVGTT, the NLGMM is subject to the following initial condi-
tions
G(0) = G0, X(0) = 0, I(0) = I0, E(0) = Eb, Y (0) = 0. (6)
All parameters are positive and variables appearing within the model are defined in
Table 1. Note that the positive superscript used in the system above is shorthand
notation for the following function
(G−Gb)+ =
G−Gb, G ≥ Gb,0, G < Gb. (7)
A similar definition is used for the functions (Gb−G)+ and (E−Eb)+. In addition,113
the functions Ginf(t) and Iinf(t) are used to account for external infusions of glucose114
and insulin into the body and can change dramatically in different tests.115
The NLGMM accounts for the concentration of glucagon in plasma but also ac-116
counts for the effects of glucagon in tissue, termed active glucagon. The idea behind117
this model is that the amount of plasma glucagon is irrelevant. Instead, it is the118
amount able to stimulate endogeneous glucose production that directly raises the119
concentration of glucose in the blood stream. This assumption is useful as it allows120
patients who suffer from hyperglucagonemia to be easily accounted for and was first121
suggested by [22] as a suitable mechanism for glucose-glucagon dynamics.122
The concentration of active glucagon is dependent upon plasma glucagon and123
will only increase if the concentration of plasma glucagon is above its basal value.124
If this criterion is met, there will be more active glucagon present in the system125
and endogeneous glucose production will increase. However, if the concentration of126
blood glucose becomes too high, the concentration of active glucagon will decrease127
to zero due to the lack of secretion of plasma glucagon and thus endogeneous glu-128
cose production will cease.129
In terms of modelling the concentration of glucagon in plasma, this model as-130
sumes that glucagon is only released from the pancreas when glucose concentration131
falls below its pre-test, basal level. It further assumes that high levels of insulin in132
plasma suppress glucagon secretion and cause the concentration in plasma to fall.133
This phenomenon has been observed in the work of [24] and should be accounted134
for in any mathematical representation of this system. The term accounting for135
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this interaction between hormones does not allow the rate of change of glucagon136
to continually decrease in the presence of increasing insulin but rather, it assumes137
that beyond a certain insulin concentration, glucagon secretion will decrease at a138
constant rate.139
140
Linear Glucagon Minimal Model Formulation (LGMM)141
The second model presented assumes that the concentration of glucose is directly142
affected by plasma glucagon and therefore omits interstitial glucagon activity. This143
system is referred to as the Linearised Glucagon Minimal Model (LGMM), as the144
rate of change of glucose depends in a linear fashion on the concentration of plasma145
glucagon.146
147
The system of equations for the LGMM is
dG
dt
= −p1(G−Gb)−XG+ δ(E − Eb) +Ginf(t), (8)
dX
dt
= −p2X + p3(I − Ib), (9)
dI
dt
= −p4(I − Ib) + p5(G−Gb)+t+ Iinf(t), (10)
dE
dt





In the case of an IVGTT, the LGMM is solved subject to the corresponding initial
conditions
G(0) = G0, X(0) = 0, I(0) = I0, E(0) = Eb. (12)
The new parameter δ is defined in Table 1.148
149
In the LGMM, the concentration of plasma glucagon is modelled in the same150
way as in the NLGMM, but the rate of change of glucose concentration is instead151
assumed to be directly proportional to the concentration of plasma glucagon. In152
this model, a fall in plasma glucagon concentration will immediately lead to a rise153
in the concentration of blood glucose, whereas an increase in plasma glucagon will154
lead to an immediate rise in glucose concentration.155
Physiological parameters156
One of the principal advantages of retaining the glucose-insulin dynamics as de-
scribed by the Minimal Model is that the glucose effectiveness (sG) and insulin
sensitivity (sI) of a patient may be estimated. Hence, estimates of these parameters
are recovered from the following equations:
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The reader is referred to [14] for more information about how these estimates are
derived. All three of these parameters (p1−3) are common to the NLGMM and
LGMM, allowing both models to compute approximations to these key parameters.
As the interactions between glucagon and glucose are modelled in a different way,
both models return different estimators of the glucagon effect. Following a similar
idea to that used in [16] to compute insulin sensitivity, if a non-zero steady state












where the subscript denotes “steady state”, and corresponds to the rate of change
of glucose when the concentration of active glucagon is steady. The glucagon Sen-












This is identical to the result given in [22].157
158
The LGMM does not contain the variable representing active glucagon and is
therefore unable to return an estimate of glucagon sensitivity. However, it is possible
to derive an alternate parameter that allows the effects of glucagon to be quantified.
Using (8), let us define the function
F (G,X,E) = −p1(G−Gb)−XG+ δ(E − Eb)
which describes the rate at which the concentration of plasma glucose changes.
Taking the derivative of this function with respect to G gives
∂F
∂G
= −p1 = −sG. (18)
This quantity describes the rate at which the concentration changes according to
the amount of glucose present in the system and is equivalent to the glucose effec-
tiveness. According to [14], ‘glucose effectiveness is defined as the enhancement of
glucose disappearance due to an increase in the plasma glucose concentration’. The
appearance of the minus sign within the equation above explains why glucose effec-
tiveness is used to describe the rate of disappearance as it cause the concentration
to decrease.
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This quantity describes the rate at which the concentration of glucose changes ac-159
cording to the amount of glucagon present in the system. It is therefore appropriate160
to refer to this quantity as glucagon effectiveness. Using the definition provided161
above for glucose effectiveness, the glucagon effectiveness parameter is defined as162
the quantitative enhancement of glucose appearance due to an increase in plasma163
glucagon concentration.164
Clearly, although glucagon effectiveness and glucagon sensitivity are derived in dif-165
ferent ways and defined differently, they both allow a patient’s response to glucagon166
to be characterised and may be used to quantify how responsive a patient is to167
glucagon. (discussed later in the manuscript).168
Model solutions169
A detailed analysis of the qualitative behaviour of solutions of the LGMM and170
NLGMM may be found in the Appendix. The LGMM consists of a system of four171
non-linear differential equations and a maximum of 10 unknown parameters, whilst172
the NLGMM consists of five non-linear differential equations and a maxmimum of173
11 unknown parameters. As a result of the complexity of both systems, both are174
solved numerically in MATLAB using the ODE45 solver. The unknown parameters175
are fitted to experimental data using LSQNONLIN, a non-linear least squares solver,176




The accuracy of solutions produced from both the LGMM and NLGMM were val-181
idated against patient data extracted from Thomaseth et al [17] before being used182
to make new predictions. As the LGMM and NLGMM are designed to be able to183
model rapid infusions of glucose, insulin or glucagon, both models were validated184
during two different types of medical test: an IVGTT, and in a test that artificially185
induces hypoglycemia via intravenous infusions of insulin.186
Validation against an IVGTT187
Model solutions from the LGMM and NLGMM were compared against experimental188
data extracted from [17], whereby an Insulin Modified IVGTT (IM-IVGTT) and a189
modified test (GC-IM-IVGTT) was performed on thirteen patients. Briefly, insulin-190
sensitivity can be probed by the administration of insulin during an IM-IVGTT,191
which can cause transient hypoglycemia in healthy insulin-sensitive patients. The192
GC-IM-IVGTT however, is a modified IM-IVGTT test, which includes a glucose193
infusion, or “glucose clamp (GC)”, in order to prevent hypoglycemia. The two dif-194
ferent tests are described by [17] as follows:195
196
“Thirteen nondiabetic volunteers [7 male and 6 female, aged between 25 and197
27 years old, with a body mass index (BMI): 22.1±0.7 kg/m2, (mean±SD) ] were198
studied in random order during standard IM-IVGTT: 0.3 g/kg glucose at time 0 and199
0.03 IU/kg insulin at 20 min and during a modified test (GC-IM-IVGTT) with ad-200
ditional glucose infusion adjusted manually to prevent plasma glucose concentration201
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from falling below 100 mg/dl. Insulin, glucose, and NEFA plasma concentrations202
were measured at frequent intervals, from 15 min before the beginning of the test203
and during the following 3 h. Plasma concentrations of C-peptide, glucagon, corti-204
sol, growth hormone, epinephrine, and norepinephrine were also measured at timed205
intervals.”206
207
The aim of the investigation by [17] was to investigate how nonesterified fatty208
acids affect the concentration of glucose during an IVGTT. However, the authors209
provide average patient concentrations of glucose, insulin and glucagon throughout210
the IM-IVGTT and GC-IM-IVGTT which allows a thorough comparison of pre-211
dictions from both the LGMM and NLGMM to all three quantities. The rational212
for using the data from Thomaseth et al was two-fold: first, the vast majority of213
research papers in the available literature that utilise IVGTTs in an investigation214
do not contain any plasma glucagon data, and second, comparing model perfor-215
mance against data obtained from two different types of IVGTT provides a more216
complete model validation. It is worth noting that while the data extracted from217
Thomaseth et al. was used to validate the model, the adaptations the authors made218
to the minimal model were not deployed in this work because the consideration219
of free fatty acid kinetics or counterregulatory responses are not prominent here.220
Furthermore, the minimal model has been ameliorated numerous times since its221
inception for different specific outputs. Which amendments to include therefore,222
are a function of the desired output.223
Modelling both an IM-IVGTT and GC-IM-IVGTT is more complicated than a224
standard IVGTT as the additional infusions of glucose and insulin that are admin-225
istered during the test must be incorporated within the mathematical models. The226
reader is referred to the Appendix for a full description of how this is conducted here.227
228
Figure 2 compares the patient data from [17] to model solutions for the LGMM,229
NLGMM and the Minimal Model. All three model simulations fit the glucose and in-230
sulin data well, while the LGMM and NLGMM provide a good representation of the231
glucagon data. The function representing insulin infusion replicates the actual dose232
well in the IM-IVGTT but overestimates the amount given in the GC-IM-IVGTT.233
The simulated predictions of glucagon from both models fit the data well, and pass234
through the majority of the errorbars indicating good accuracy. The goodness of fit235
values computed from all three models in this example are contained within Table236
2 and indicate that all models provide highly accurate solutions here.237
238
Validation against hypoglycemic data239
LGMM and NLGMM simulations were also compared to the results of Bolli et al.,240
presented in [25]. The aim of the investigation by these authors was to determine241
the role of intraislet insulin in the response of glucagon to hypoglycemia. In the ex-242
periments conducted in this work, hypoglycemia was artificially induced in both a243
control group and a group of patients with diabetes by infusing patients with insulin244
intraveneously. Upon completion of the study, the authors were able to deduce that245
glucagon response to hypoglycemia induced by hyperinsulinemia is independent of246
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Figure 2: Model validation. Model simulations produced by the LGMM (blue
lines), NLGMM (red lines) and the minimal model (black dashed lines) for the
two different IVGTT’s (mean data and SEM illustrated by circles and error-bars)
presented in Thomaseth et al 2014 [17]. A, B and C shows the predictions for the
insulin modified IVGTT, while D, E and F illustrates the results for the IVGTT
with glucose infusion. A and D represent blood glucose concentration, B and E
represent plasma insulin and C and F represent plasma glucagon concentration
Dataset Model Glucose Insulin Glucagon
(IM-IVGTT) LGMM 0.994 0.984 0.779
NLGMM 0.997 0.993 0.850
MinMod 0.990 0.990 -
(GC-IM-IVGTT) LGMM 0.981 0.799 0.841
NLGMM 0.990 0.754 0.937
MinMod 0.992 0.766 -
Table 2: Goodness of fitness values (R2) of all model simulations presented in Figure
2.
intra-islet and circulating insulin.247
The experiments within the above named work may be replicated using the mod-248
els proposed here. However, the hyperinsulinemia triggered by the intravenously249
administered insulin must be modelled separately and provided as an additional250
input to the LGMM, NLGMM and Minimal Model.251
252
According to [25], the participants in the study are described as follows:253
254
“Seven normal healthy volunteers within 10% of ideal body weight and five age-255
and weight-matched insulin-dependent diabetic subjects were studied after obtain-256
ing fully informed consent. The normal subjects, ranging in age from 19 to 35 years257
(26±3 years, mean±SEM), had been on a weight-maintaining diet (300 g carbohy-258
drate/d) for at least 1 week before all studies. The diabetic subjects had diabetes259
of 13-15 month duration and were C-peptide deficient (0.08±0.02 ng/ml before and260
0.08±0.04 ng/ml after 1 mg glucagon given intravenously).”261
262
The experimental studies that are referred to in this paper concern both the control263
and diabetic group being infused with insulin intravenously at a rate of 30mU/m2264
per minute for an hour from the fasting state. Blood glucose concentrations, plasma265
insulin and plasma glucagon concentrations were measured at frequent intervals and266
population averages in both groups were taken to determine the mean group re-267
sponse across the test.268
The Minimal Model is not designed to simulate this type of experiment as it269
does not account for the effects of glucagon. The LGMM and NLGMM however270
are suitable for predicting glucose and hormonal responses, therefore this data was271
chosen for validation to show their ability to simulate different tests with accuracy.272
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Group Model Glucose Insulin Glucagon
Control LGMM 0.942 0.920 0.967
NLGMM 0.948 0.917 0.967
MinMod 0.666 0.921 -
Diabetic LGMM 0.904 0.787 0.983
NLGMM 0.846 0.792 0.969
MinMod 0.887 0.801 -
Table 3: Goodness of fitness values (R2) of all model simulations presented in Figure
3.
The reader is referred to the Appendix for further details of how model results are273
produced in this example.274
The original patient data as given by [25] and model solutions from the LGMM,275
NLGMM and Minimal Model are presented in Figure 3, accompanied by goodness276
of fit values in Table 3. It is very clear that the solutions from the LGMM and277
NLGMM closely match the given patient data for glucose, insulin and glucagon in278
both the control and diabetic groups. The predicted plasma glucagon concentra-279
tions are incredibly accurate with both new models fitting the data values almost280
exactly. The Minimal Model struggles to fit the glucose data in the control group281
and performs worse than the LGMM and NLGMM. It does however provide a good282
fit to the glucose data in the diabetic group which is indicative of patients in this283
group being less sensitive to the effects of glucagon.284
Figure 3: Model simulations produced from both the LGMM and NLGMM for
the insulin induced hypoglycemic tests conducted by [25]. A, B and C shows the
predictions for the control group, while D, E and F depicts the results for the
diabetic group. Blue lines correspond to solutions from the LGMM, red lines to
solutions from the NLGMM and the black dashed lines to the Minimal Model.
Experimental data from [25] is shown as triangles.
Model comparison and predictions285
Figures 2 and 3 illustrate the ability of the LGMM and the NLGMM to provide ac-286
curate approximations during both an IVGTT and tests that induce hypoglycemia287
by infusing a patient with insulin. The performance of both models may now be288
compared in more detail to discern whether one model is significantly more appro-289
priate than the other.290
Comparing the LGMM and NLGMM291
A simple way to initially compare the performance of the two new models is by292
comparing values obtained from the Akaike Information Criterion (AIC) and the293
Bayesian Information Criterion (BIC) in the examples considered above. The AIC294
and BIC are penalised-likelihood criteria, often used during model selection and295
are representative of the distance between the fitted likelihood of a model and the296
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Test Type Model AIC AICc BIC
IM-IVGTT LGMM 552.67 558.06 325.13
NLGMM 683.07 689.57 457.64
GC-IM-IVGTT LGMM 680.50 680.70 423.77
NLGMM 691.62 691.82 434.89
Insulin Infusion (Control Group) LGMM 277.70 286.87 168.82
NLGMM 276.19 287.68 168.87
Insulin Infusion (Diabetic Group) LGMM 262.84 273.85 170.73
NLGMM 268.40 279.93 177.72
Table 4: Values of the AIC, modified AIC and BIC computed from the model
simulations in the two examples used to validate the LGMM and NLGMM.
unknown true likelihood function of the data. The only difference between the two297
measures is that the BIC penalises model complexity more heavily.298
The second order AIC (AICc) can be calculated to account for smaller sample sizes299
which does penalise the use of additional parameters more heavily than the usual300
AIC. In what follows, values from all three criteria are used to compare the LGMM301
and NLGMM. The AIC, second order modified (AICc) and BIC values for the two302
validation outputs are contained in Table 4. The LGMM yields the minimum AIC303
values for three out of the four tests (IM-IVGTT, GC-IM-IVGTT and the insulin304
infusion diabetic group), with the NLGMM yielding the minimum AIC value for the305
insulin infusion control group. However, the AICc and BIC values corresponding to306
the LGMM are smaller in all cases, with significantly smaller values recorded for307
the IM-IVGTT and control group. The AICc considers the smaller sample size and308
therefore lends credence to the LGMM being the most appropriate model for the309
insulin infusion results. Moreover, the LGMM model possesses a smaller parameter310
space than the NLGMM, meaning less potential error during parameter estimation.311
Hence on the basis of these tests, it seems evident that the LGMM is the most312
appropriate model to use.313
314
Another robust test that can be used to compare model performance is to deter-315
mine how good both models are at accurately recreating patient profiles and model316
parameters. This test requires simulated data instead of real patient data so that a317
very large amount of tests may be run and statistically unbiased conclusions may318
be drawn. Using precise, known model parameters also allows the exact error in the319
parameter estimates to be computed.320
In this example, a selection of randomly generated parameters values are input321
into both the LGMM and NLGMM and used to simulate blood glucose, plasma322
insulin and plasma glucagon profiles during an IVGTT. This data is then distorted323
with a specified level of noise and used to create a “virtual patient cohort” which324
is passed into both models. The models are then fitted to the data and used to325
estimate the parameters which are assumed to be unknown. The returned param-326
eter estimates may then be directly compared to the exact values that were used327
originally, facilitating a comparison of model performance.328
As the glucose effectiveness and insulin sensitivity of a patient are of real clini-329
cal significance, this investigation focuses solely on the accuracy of the estimates330
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obtained for these parameters. The inclusion of noise within the data represents po-331
tential errors in the way that measurements are taken, collected and/or recorded.332
Investigating how the estimates of glucose effectiveness and insulin sensitivity re-333
turned by both models are affected by noise will determine how viable it is to use334
these models when there is a reasonable degree of error in the patient data. The335
accuracy of the predicted values of glucose effectiveness and insulin sensitivity was336
investigated by considering the relative percentage error (RPE) in each approxima-337
tion. The RPE in each approximation was calculated using the following formulae:338
RPE in Glucose Effectiveness =
∣∣∣∣sG − sAGsG
∣∣∣∣× 100, (19)
RPE in Insulin Sensitivity =
∣∣∣∣sI − sAIsI
∣∣∣∣× 100, (20)
where the superscript A denotes the returned approximation to the parameter of339
interest. If the relative percentage error is close to zero, the returned approximation340
to the parameter is highly accurate. A complete description of how these simula-341
tions are conducted is contained in a flowchart within Figure 4, representing a total342
of 500 simulations.343
344
Figure 4: A flowchart indicating how parameter estimates are computed and com-
pared during the comparison of the LGMM and NLGMM
The model parameters used in this test are described fully in Additional file 1:345
Table S1 in the appendix. The chosen ranges for the parameters p1 − p5 are taken346
from Nittala et al [26]. However, the ranges used for the parameters p6 − p11 and347
δ were chosen after empirical testing using trial and error by the authors. This348
consisted of using the corresponding fitted values for these parameters in example349
1 as the median value of these quantities and picking a suitable range of values350
either side of the median that provided realistic glucose, plasma insulin and plasma351
glucagon behaviour.352
Figure 5 presents a series of boxplots depicting the relative percentage error be-353
tween the estimated and observed values of glucose effectiveness (sG) and insulin354
activity (sI) obtained from both the LGMM and NLGMM. Equivalent results ob-355
tained from the Minimal Model are also presented to allow further comparison of356
model performance. A series of descriptive statistics that compare the median and357
interquartile range of the relative percentage error produced from each model are358
further contained in Table 5.359
It is evident in all boxplots that the results produced from the LGMM are far360
more accurate than those produced from the NLGMM. The results obtained from361
the LGMM consistently have a much lower spread than the NLGMM, as indicated362
by the much smaller box size. The interquartile range and hence box size increases363
as the amount of noise in the patient data increases for all models, which indicates364
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Figure 5: Boxplots of the estimates of glucose effectiveness and insulin sensitivity
returned from the LGMM (abbreviated to LM here), NLGMM (abbreviated to
NLM) and the Minimal Model (MM). The top panel shows the boxplots for the
RPE in glucose effectiveness and the bottom panel shows the boxplots for the RPE
in insulin sensitivity. The three boxplots above each model label represent 0%, 5%,
and 10% noise respectively from left to right.
that the accuracy of the estimates of glucose effectiveness and insulin sensitivity pro-365
duced by all models decreases with noise. This is unsurprising as errors in patient366
data will increase the difficulty in model-fitting and lead to increased uncertainty367
in parameter estimation. There are also significantly more outliers obtained in this368
case, not all of which are shown here due to the scale chosen. However, the median369
values of glucose effectiveness and insulin sensitivity produced from the LGMM are370
still much closer to zero than those obtained by the NLGMM when there is noise371
in the data, and therefore the LGMM still proves to be a more accurate model in372
these cases.373
The results produced from the Minimal Model are far more accurate than the374
NLGMM but comparable to those produced from the LGMM. Furthermore, the375
median and interquartile range produced from both LGMM and NLGMM are sim-376
ilar at the 5% and 10% noise levels. There is evidence however that the Minimal377
Model produces the more accurate approximations to glucose effectiveness and in-378
sulin sensitivity with zero noise in the patient data as the interquartile range is379
much smaller than that computed for the LGMM.380
A more definitive comparison between the LGMM, NLGMM and Minimal Model381
may be obtained by comparing the predictions from all models for each dataset382
using the Kruskal-Wallis test. The Kruskal-Wallis test checks the null hypothesis383
that data from all three models originate from the same distribution against the384
alternative hypothesis that they do not. As can be seen in Table 5, the p-values385
produced in all cases for this test are significant at the 5% level and consequently,386
the data produced from all three models does not come from the same distribution.387
The performance of the LGMM and NLGMM may be compared directly using388
the Mann-Whitney U-test and again, statistically significant results at the 5% level389
are obtained for all of the simulations produced here (not shown here). Given that390
the medians produced for the LGMM are much smaller than those produced for the391
NLGMM and that the interquartile range is persistently smaller for the LGMM, the392
results of these tests indicate that the approximations computed from the LGMM393
are statistically more accurate than the NLGMM. However, the performance of the394
LGMM is comparable to that of the Minimal Model.395
396
Investigating the response of glucagon during an IVGTT397
As both models have been validated against patient data and have been compared398
against one another to contrast model performance, analysis concludes with an399
investigation into how the concentration of plasma glucagon varies during glucose400
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LGMM NLGMM MinMod
Noise Level Parameter Median IQR Median IQR Median IQR p-value
0% sG 0 1.7362 -1.2291 49.1232 0 0.0238 0.0031
sI 0 1.5644 10.5997 40.3733 0 0.0091 <0.0001
5% sG -6.2099 30.8770 -13.2109 73.9800 -5.8340 34.3679 0.0041
sI -7.7208 40.1055 16.6060 52.5382 -5.1386 38.8835 <0.0001
10% sG -6.7471 44.0449 -13.6528 83.1426 -3.3342 44.1309 0.0001
sI -7.1037 69.7317 12.6253 69.7497 -7.6116 71.9373 <0.0001
Table 5: Statistical Comparison of the relative percentage error in the approxima-
tions to glucose effectiveness and insulin sensitivity, produced from the LGMM,
NLGMM and Minimal Model. The medians of each dataset and the interquartile
range (IQR) are presented here and the p-values produced from the Kruskal-Wallis
test at the 95% confidence level that tests if the data from each model is obtained
from the same distribution.
tolerance testing. In this example, the response of glucagon during an IVGTT was401
investigated. Particular attention was given to the relationship between insulin and402
glucagon, in an attempt to determine how glucagon may be suppressed during403
periods of hyperglycemia. As a result, all parameter values in this example are404
fixed and set equal to the fitted parameter values obtained from the first dataset in405
Figure 2, (see the Appendix for details) apart from p11, which governs how sensitive406
glucagon suppression is for any given concentration of insulin.407
408
Figure 6 illustrates how different maximum rates of insulin-dependent glucagon409
suppression influences glucagon concentration, during an IVGTT for the LGMM410
and NLGMM. In this example, blue lines correspond to smaller values of p11 which411
indicate relatively little glucagon suppression, and red lines corresponds to larger412
values, which indicate more significant glucagon suppression. Both models predict413
that patients with a higher sensitivity (larger p11) of insulin-mediated glucagon414
suppression, exhibit a lower glucagon concentration, compared to a non-sensitive415
patient.416
417
Figure 6: Variations in endogenous glucagon production. Endogeneous
glucagon production during an IVGTT for a range of of values of p11 that corre-
spond to differing maximum rates of glucagon suppression by insulin for the LGMM
(A) and NLGMM (B). Blue lines correspond to smaller values of p11 and red lines
correspond to larger values. Parameter values used for the simulations are located
in Additional file 2: Table S2 in Appendix D, with the value of p11 varying between
0 and 2 in increments of 0.1 between simulations.
Figure 6 also illustrates the fundamental differences between how the glucagon418
metabolism in the LGMM and NLGMM is simulated during an IVGTT. The LGMM419
predicts that regardless of varying degrees of insulin-mediated glucagon suppres-420
sion, glucagon concentration will peak and plateau at aproximately 150% of basal,421
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whereas the NLGMM reaches almost 200% of the basal glucagon concentration,422
with little sign of decreasing. Ultimately, the metabolism of glucagon hinges upon423
the concentration of glucose, either by direct secretion during hypoglycaemia, or424
indirectly via insulin-mediated inhibition during hyperglycemia. In this instance,425
glucagon concentration is able to recover quicker within the LGMM, due to the426
omission of interstitial glucagon activity, given that the rate of change of plasma427
glucagon is directly proportional to the concentration of glucose. The NLGMM428
however, does include interstitial glucagon activity, rendering the concentration of429
plasma glucagon a less useful metric than the amount of effective glucagon working430
in the system at a given time. These simulations suggest that first, manipulation431
of p11 within both models facilitates simulation of inter-individual variation with432
respect to insulin-mediated glucagon suppression, and second, that the NLGMM is433
perhaps better suited to simulate patients who suffer from hyperglucagonemia.434
435
Investigating the response of glucagon during periods of hypoglycemia436
The final example presented in this work considers how glucagon response within437
a patient with Type 1 diabetes mellitus (T1DM) varies during periods of hypo-438
glycemia. The most novel aspect of the two new models introduced within this439
work is that they both seek to describe the dynamics between glucose, insulin and440
glucagon, given that the relationship between glucose and glucagon is key when a441
patient experiences hypoglycemia.442
443
Within this example, model simulations explored the possible variations between444
patients. The simulated test represents a patient with T1DM receiving an intra-445
venous infusion of one unit of insulin in the fasting state and measures how different446
values of glucagon effectiveness and glucagon sensitivity affect the response of both447
blood glucose and plasma glucagon over a three hour period, assuming that no448
glucose is ingested or administered to correct sugar levels.449
All parameters within this example, except for glucagon effectiveness (δ) in the450
case of the LGMM and glucagon sensitivity (sE) in the case of the NLGMM, are451
fixed and detailed within the Appendix. It should be noted that some of the param-452
eter values used in this example may not correspond exactly to the physiological453
parameters that one would expect for a Type 1 diabetic so the predictions produced454
here should be regarded primarily as qualitative rather than quantitative.455
456
Figure 7 shows the glucose and plasma glucagon concentration profiles of T1DM457
patients produced in this test. The LGMM predicts that a patient with a higher458
glucagon effectiveness will experience a rapid reduction in plasma glucose, followed459
by a quicker, full recovery to basal levels (7 A). Conversely, a patient who is glucagon460
ineffective, will fail to recover to pre-test glucose concentrations during the 180461
minute simulation. The NLGMM model predicts that there will be no difference462
between a glucagon sensitive or insensitive individual for the first 50 minutes of the463
test (7 B ). However, glucagon effective patients will recover before 150 minutes,464
whereas patients who are glucagon ineffective will fail to recover to basal glucose465
concentrations. Outputs for both models are intuitive, with the predominant differ-466
ences between the LGMM and NLGMM resting in the recovery time. The LGMM467
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predicts glucagon sensitive individuals may recover rapidly, compared to the NL-468
GMM, which predicts a much more delayed recovery time. Again, this behaviour469
is a function of how the LGMM and NLGMM each represent glucose metabolism,470
with the LGMM rate of change of glucose concentration being directly dependent on471
plasma glucagon, leading to an immediate fall in plasma glucose. The blood glucose472
concentrations presented here for a patient with a normal response to glucagon are473
qualitatively identical to those presented in [25] for patients with type 1 diabetes474
and normal response to glucagon which further validates the predictions produced475
from both models.476
477
Figure 7: Statistical comparison of glucose effectiveness and insulin sensi-
tivity. The evolution of blood glucose and plasma glucagon concentrations after an
injection of one unit of insulin for patients with different degrees of glucagon sen-
sitivity and glucagon effectiveness. A and C present the results from the LGMM,
while B and D present the results from the NLGMM. The colour scheme indicates
low glucagon effectiveness / sensitivity (dark blue) to high glucagon effectiveness /
sensitivity. The value of δ varies between 0.0001 and 0.01 in increments of 0.005,
whilst the value of sE varies between 1 × 10−5 and 5 × 10−4 in increments of
2.45 × 10−5. All of the parameter values used for these simulations are located in
Additional file 3: Table S3 in Appendix D.
Figure 7 also presents the simulated plasma glucagon concentration profiles from478
the LGMM and NLGMM (7 C and 7 D), which are are virtually identical in every479
case, indicating that an individual with very low glucagon effectiveness / sensitiv-480
ity experiences a large increase in the concentration of plasma glucagon. The only481
difference between the LGMM and NLGMM, similar to the glucose concentration482
profiles, is the delayed recovery response-time of the NLGMM compared to the483
LGMM. It is further evident that type 1 diabetics with an impaired response to484
glucagon would be unable to raise their blood glucose levels and would require an485
infusion of glucose to recover from hypoglycemia. Type 1 diabetics with a normal486
response to glucagon however are able to recover from hypoglycemia without insulin487
infusion.488
489
Model Considerations and Applications490
Both the LGMM and NLGMM fit well to the glucose, glucagon and insulin profiles491
from modified and glucose infusion IVGTT data. The ability of both models to492
replicate the data was compared using the AIC and BIC penalised-likelyhood crite-493
rion tests, which suggested that the LGMM is considered the superior model with494
respect to simulating an IVGTT, as well as for insulin infusion models. This finding495
was bolstered during the parameter re-estimation analysis, where the LGMM was496
statistically more accurate when predicting glucose effectiveness and insulin sensi-497
tivities for a “virtual patient cohort” given 0%, 5% and 10% noise. While the LGMM498
appears to best the NLGMM in terms of replicating IVGTT and insulin infusion499
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data, simulations of blood glucose and glucagon concentrations in Figure 6 and500
Figure 7 present the merits of the linear and non-linear descriptions of glucagon501
metabolism. Simulations of both models allow prediction of how inter-individual502
variations in glucagon effectiveness and sensitivity can affect plasma glucose and503
glucagon concentrations. LGMM and NLGMM simulations of IVGTT and insulin504
infusion data stand strong compared to the Minimal Model ouputs in Figures 2 and505
3 for glucose and insulin outputs.506
It is important to note that the driving force of this work was not to improve the507
accuracy of predicting glucose effectiveness (sG) and insulin sensitivity (sI) param-508
eters with respect to the Minimal Model, but rather, to expand the mathematical509
metabolic portrait to include the role of glucagon, given the current surge of interest510
it has received in the field of diabetology.511
512
Conclusion513
Presented here are two mathematical models of glucagon-glucose-insulin metabolism,514
used to simulate an IVGTT. The first, assumes a complex, non-linear glucose-515
glucagon-insulin relationship, while the second assumes that the rate of change516
of glucose concentration is proportional to the concentration of plasma glucagon.517
Both models accurately replicate insulin-modified and glucose infusion IVGTT518
data, while also being able to re-estimate the key physiological parameters, glucose519
effectiveness (sG) and insulin sensitivity (sI). Inclusion of glucagon dynamics allow520
estimation of two new parameters, glucagon sensitivity (sE) and glucagon effective-521
ness (δ), which describe the quantitative enhancement of glucose appearance due522
to an increase in plasma glucagon concentration. Perturbation of these parameters523
facilitates investigation of inter-individual variation of glucagon sensitivity and the524
resulting changes on plasma glucose and glucagon concentration. The LGMM and525
NLGMM allow the role of glucagon during an glucose tolerance testing and insulin526
infusion to be investigated, as well as providing a mathematical platform from which527
potential glucagon-based therapeutics may be explored.528
Appendix A: Model Analysis
A.1 Qualitative study of solutions
Due to the inherent non-linearity within both models, it is impossible to obtain an-
alytical solutions of either system and numerical methods must be used instead to
obtain approximate solutions. It is possible however to obtain qualitative informa-
tion about the behaviour of solutions of both plasma insulin and plasma glucagon
without being able to explicitly solve for I(t) and E(t). In what follows in this
section, the qualitative behaviour of the NLGMM is discussed, as the equations
modelling the concentration of plasma insulin and plasma glucagon are identical in
both systems and a separate analysis of both systems here is unnecessary.
If one attempts to solve (3) in isolation from the rest of the NLGMM, the solution
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is obtained for t ≥ 0. This solution is of little practical use as G(t) is unknown
but it can be immediately observed that when G(t) > Gb, I(t) > Ib which is what
should happen as insulin is released to counteract an increase in glucose. However,
if G(s) < Gb, the exact solution
I(t) = Ib + (I0 − Ib)e−p4t (22)
is obtained, which still satisfies I(t) ≥ Ib. It may be deduced therefore that the
equation modelling the concentration of plasma insulin in both models does not
allow the concentration to drop below the basal level. This is also true of the Minimal
Model.
The behaviour of plasma glucagon is more complex as it is assumed to depend
on both glucose and insulin and the ODE is non-linear. However, when a patient
is experiencing hyperglycemia and the concentration of plasma insulin is very high,
(3) may be simplified into the following equation
E′(t) = −p6(E − Eb)− p11. (23)
This ODE possesses the exact solution







where the initial condition E(0) = Eb has been applied. As t → ∞, this solution
tends to the constant value




which is the minimum possible concentration of plasma glucagon and a steady state




The integral representations of the solutions of both interstitial insulin and glucagon









Given that both integrands are non-negative for all possible values of t, it may be
deduced that the concentrations of insulin and glucagon in tissue will always be
non-negative. This is to be expected as it is clearly impossible to have negative
concentrations of hormones in tissue, but it is reassuring that all model simulations
are realistic in this sense.
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A.2 Investigating the existence of critical points
Determining the existence of steady-state solutions of both the NLGMM and
LGMM is a useful exercise as such solutions allow characterisation of the long
term behaviour of solutions obtained from both models.
As a system of differential equations can only possess one or more critical points
if it is autonomous, it follows that the terms involving (G − Gb)+ and (Gb − G)+
must vanish simultaneously to suppress the explicit appearance of the time variable.
From this information, one can deduce that the only possible critical point of the
NLGMM is
(G?, X?, I?, E?, Y ?) = (Gb, 0, Ib, Eb, 0). (29)
It similarly follows that the only critical point of the LGMM is
(G?, X?, I?, E?) = (Gb, 0, Ib, Eb). (30)
In both cases, the critical point corresponds to the physical situation of the patient
not being administered glucose and thus their body remaining in the fasting state.
A.3 Classifying the long term behaviour of model solutions
Having found the critical points of both systems, it is now of interest to classify their
nature and determine how model solutions behave in the limit t→∞. The stability
of these critical points may be determined by evaluating the Jacobian matrices of
both systems of equations at the critical point (see [27] for example). In the case of
the NLGMM, the requisite matrix is
J? =

−p1 −Gb 0 0 Gb
0 −p2 p3 0 0
0 0 −p4 0 0
0 0 −αp11 −p6 0
0 0 0 p9 −p8
 (31)















λ = −p1,−p2,−p4,−p6,−p8. (33)
As all model parameters appearing in the NLGMM are positive, these eigenvalues
are negative and hence the critical point is stable. This means that all solutions
produced from this model will eventually return to the pre-test fasting levels ob-
tained for a patient.
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In the case of the LGMM, the Jacobian matrix evaluated at the critical point is
J? =

−p1 −Gb 0 δ
0 −p2 p3 0
0 0 −p4 0
0 0 −αp11 −p6
 , (34)
and the eigenvalues of this matrix are
λ = −p1,−p2,−p4,−p6. (35)
As all obtained eigenvalues are again negative here, this critical point is also stable
and all model solutions will eventually return to a patient’s pre-test fasting levels.
Appendix B: Modelling an IM-IVGTT and GC-IM-IVGTT
In a standard IVGTT, glucose is administered intraveously only at the beginning
of the test and there is no infusion of insulin. In this situation, the Minimal Model
and both the LGMM and NLGMM assume that the initial concentrations of plasma
glucose and plasma insulin are very high at the beginning of the test. These as-
sumptions have the advantage of simplicity and have proven to produce accurate
predictions in numerous investigations.
The infusion of insulin that is given after 20 minutes in both the IM-IVGTT and
GC-IM-IVGTT needs to be directly accounted for within any approximating model
to ensure that the predicted glucose response is accurate. This requires the use of
a suitable function Iinf (t) to model this dose. Based on the details provided about
the average patient BMI and dosage given in [17], the insulin infusion is modelled
using the following function:
Iinf (t) = 3920 e
−8|t−20|. (36)
This function has been chosen as it represents a dose administered over a maximum
of 60 seconds. The value 3920 was determined by LSQNONLIN when this function
was fitted to the dataset for plasma insulin given in the IM-IVGTT.
In the GC-IM-IVGTT, Thomaseth et al. do not give any indication as to how much
glucose is infused to prevent hypoglycaemia, rather. Instead, the authors indicate
that the additional glucose infusion is adjusted manually to prevent hypoglycaemia.
In the absence of more specific information, it is assumed that when glucose con-
centration reaches 100 mg/dl, it ceases to vary, and hence (1) is replaced by the
alternate equation:
G′(t) = 0.
Whilst this is not a true representation of how the glucose concentration actually
behaves, it does make it possible to examine whether the simulated behaviour of
glucagon is qualitatively correct or not in this case.
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Appendix C: Modelling an Insulin Infusion test
In an insulin infusion test, insulin is administered intravenously at a constant rate
for a substantial period of time. Within this work, the insulin infusion term within
equations (3) and (10) is chosen to be
Iinf(t) =
Id, 0 ≤ t ≤ 65,0, t > 65,
where Id is the provided dosage of insulin with corresponding units µU/ml min
−2.
This value may be computed using the information regarding dosage provided by
[25].
The initial conditions for both the LGMM and NLGMM are also much simpler
in an insulin infusion test as the initial concentrations of blood glucose and plasma
insulin are assumed to be at their basal level. The initial conditions for the NLGMM
in this case are:
G(0) = Gb, X(0) = 0, I(0) = Ib, E(0) = Eb, Y (0) = 0, (37)
and the initial conditions for the LGMM are
G(0) = Gb, X(0) = 0, I(0) = Ib, E(0) = Eb. (38)
As a result, only 10 unknown parameters appear in the LGMM and 11 unknown
parameters appear in the NLGMM in this test.
Appendix D: Simulation parameters
The following Table contains the parameters used to investigating the response of
glucagon during an IVGTT.
Parameter Median Value Smallest Value Largest Value
p1 0.01 0.001 0.1
p2 0.05 0.01 0.9
p3 1× 10−5 1× 10−6 1× 10−4
p4 0.225 0.05 0.4
p5 0.005 0.001 0.009
p6 0.055 0.01 0.1
p7 1× 10−4 1× 10−5 1× 10−3
p8 0.26 0.1 0.52
p9 5× 10−3 1× 10−4 9× 10−3
p11 0.125 0.5 2
δ 0.01 0.001 0.1
Gb 85 70 100
Ib 12 7 17
Eb 65 50 85
Table S1 The range of parameter values used to create a virtual cohort of patient
data. The corresponding units for each quantity are described in Table 1.
.
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p8 No 0.13





Table S2 Parameter values used in the example investigating glucagon suppression
caused by insulin. The corresponding units for each quantity are described in Table
1.
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Table S3 Parameter values used in the example investigating the response of
glucagon and glucose due to an infusion of insulin. The corresponding units for
each quantity are described in Table 1.
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